Analysis of Lipid Biomarkers of Exposure and Host Response

Stopped early · Not applicable

Conditions studied: Cigarette Smoking

In brief

The purpose of this prospective, open-label, clinical trial is to establish the feasibility and validity of exhaled breath condensate (EBC) biomarkers for use in studies designed to evaluate harm reduction strategies of smoking. This will be accomplished by measuring selected markers in EBC believed related to the pathogenesis of lung disease before and after a smoking cessation intervention.

Key facts

Study ID

NCT00493831

Run by

University of Nebraska

People needed

24

Starts

2005-08-23

Expected to finish

2007-09-09

Last updated by the study team

2023-09-07

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Smoke at least 5 pack years
• Have a stable smoking habit for 3 months
• Be willing to make a serious quit attempt and
• Be able to use nicotine replacement therapy

You may not qualify if…

• Regular use of an anti-inflammatory medication
• Presence of an inflammatory lung disease
• Unstable medical condition

Where it is running

• Unversity of Nebraska Medical Center — Omaha, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.